Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

12.15 +0.15 (+1.25%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	270,697
Open	11.95
Bid (Size)	12.14 (2,800)
Ask (Size)	12.15 (500)
Prev. Close	12.00
Today's Range	11.68 - 12.86
52wk Range	6.565 - 13.57
Shares Outstanding	28,985,019
Dividend Yield	19.75%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

From Jade Biosciences

Via GlobeNewswire

Performance

YTD	+19.8%	+19.8%
1 Month	+21.5%	+21.5%
3 Month	+53.8%	+53.8%
6 Month	+64.9%	+64.9%
1 Year	+19.8%	+19.8%

More News

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

November 08, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

November 03, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

October 07, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Announces $135 Million Private Placement

October 07, 2025

From Jade Biosciences

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 01, 2025

Via Benzinga

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

September 02, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in Upcoming Conferences

August 25, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Posts Wider Loss in Q2 ↗

August 13, 2025

Via The Motley Fool

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

From Jade Biosciences

Via GlobeNewswire

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 17, 2025

Via Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2025

Via Benzinga

Jade Biosciences to Participate in Two Upcoming Investor Conferences

July 08, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

July 01, 2025

From Jade Biosciences

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 09, 2025

Via Benzinga

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

June 09, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

June 02, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

From Jade Biosciences

Via GlobeNewswire

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025

From Jade Biosciences

Via GlobeNewswire

Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

May 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 09, 2025

Via Benzinga

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗

May 09, 2025

Via Benzinga

Frequently Asked Questions

Is Jade Biosciences, Inc. - Common Stock publicly traded?

Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Jade Biosciences, Inc. - Common Stock trade on?

Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?

The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market

What is the current price of Jade Biosciences, Inc. - Common Stock?

The current price of Jade Biosciences, Inc. - Common Stock is 12.15

When was Jade Biosciences, Inc. - Common Stock last traded?

The last trade of Jade Biosciences, Inc. - Common Stock was at 11/24/25 04:00 PM ET

What is the market capitalization of Jade Biosciences, Inc. - Common Stock?

The market capitalization of Jade Biosciences, Inc. - Common Stock is 352.17M

How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?

Jade Biosciences, Inc. - Common Stock has 352M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.